| Teresa Austin Karre, MD | |
|
8303 Dodge St, Omaha, NE 68114-4108 | |
| (402) 354-4540 | |
| (402) 354-4535 |
| Full Name | Teresa Austin Karre |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 8303 Dodge St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801057088 | NPI | - | NPPES |
| 470376604-22 | Medicaid | NE | |
| 1801057088 | Medicaid | IA |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Methodist Hospital | Omaha, NE | Hospital |
| Montgomery County Memorial Hospital | Red oak, IA | Hospital |
| Methodist Fremont Health | Fremont, NE | Hospital |
| Clarinda Regional Health Center | Clarinda, IA | Hospital |
| Saunders Medical Center | Wahoo, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nebraska Methodist Hospital | 6901707447 | 118 |
| Methodist Fremont Health | 7911258520 | 67 |
| Jennie Edmundson Memorial Hospital | 9537064837 | 32 |
News Archive
A selection of health policy stories from New York, California, the District of Columbia, North Carolina and Georgia.
It's common sense: It is generally better to help the disabled or elderly stay in their homes and communities than to put them in institutionalized care. At home, they have a higher quality of life and a social support system.
Bariatric surgery can reverse type 2 diabetes in severely obese people, reducing or eliminating the need for medications, and improve other serious health problems such as high blood pressure and sleep apnea, but it still remains to be determined which patients with type 2 diabetes will benefit most from surgery.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 3 days ago
| Entity Name | Nebraska Methodist Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689628372 PECOS PAC ID: 6901707447 Enrollment ID: O20040116000781 |
News Archive
A selection of health policy stories from New York, California, the District of Columbia, North Carolina and Georgia.
It's common sense: It is generally better to help the disabled or elderly stay in their homes and communities than to put them in institutionalized care. At home, they have a higher quality of life and a social support system.
Bariatric surgery can reverse type 2 diabetes in severely obese people, reducing or eliminating the need for medications, and improve other serious health problems such as high blood pressure and sleep apnea, but it still remains to be determined which patients with type 2 diabetes will benefit most from surgery.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 3 days ago
| Entity Name | Methodist Fremont Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235618216 PECOS PAC ID: 7911258520 Enrollment ID: O20181017000110 |
News Archive
A selection of health policy stories from New York, California, the District of Columbia, North Carolina and Georgia.
It's common sense: It is generally better to help the disabled or elderly stay in their homes and communities than to put them in institutionalized care. At home, they have a higher quality of life and a social support system.
Bariatric surgery can reverse type 2 diabetes in severely obese people, reducing or eliminating the need for medications, and improve other serious health problems such as high blood pressure and sleep apnea, but it still remains to be determined which patients with type 2 diabetes will benefit most from surgery.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Teresa Austin Karre, MD Po Box 2797, Omaha, NE 68103-2797 Ph: (402) 354-4230 | Teresa Austin Karre, MD 8303 Dodge St, Omaha, NE 68114-4108 Ph: (402) 354-4540 |
News Archive
A selection of health policy stories from New York, California, the District of Columbia, North Carolina and Georgia.
It's common sense: It is generally better to help the disabled or elderly stay in their homes and communities than to put them in institutionalized care. At home, they have a higher quality of life and a social support system.
Bariatric surgery can reverse type 2 diabetes in severely obese people, reducing or eliminating the need for medications, and improve other serious health problems such as high blood pressure and sleep apnea, but it still remains to be determined which patients with type 2 diabetes will benefit most from surgery.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 3 days ago
Audrey J Lazenby, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Emile @ 42nd St, Omaha, NE 68198 Phone: 402-559-4186 Fax: 402-559-6018 | |
Shane K. Kohl, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Omaha, NE 68114 Phone: 402-354-4540 Fax: 402-354-4535 | |
Stanley J Radio, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 988102 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 402-559-4186 Fax: 402-559-6018 | |
Christine Petricek Hans, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Omaha, NE 68114 Phone: 402-354-4540 Fax: 402-354-4535 | |
Dr. Diana L Nevins, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Omaha, NE 68114 Phone: 402-354-4540 Fax: 402-354-4535 | |
Dr. Marc R Hapke, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 909 N 96th St, Suite 201, Omaha, NE 68114 Phone: 402-330-4555 Fax: 402-934-0945 | |
Bryan Scott Teruya, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 4101 Woolworth Ave, Department Of Pathology, Omaha, NE 68105 Phone: 402-995-3218 |